OncoMatch/Clinical Trials/NCT07132684
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
Is NCT07132684 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Daunorubicin/Idarubicin and Cytarabine for aml, adult.
Treatment: Daunorubicin/Idarubicin · Cytarabine · Azacitidine · Venetoclax — This study is a multicenter, randomized, controlled phase III clinical trial aimed at comparing the efficacy of two induction chemotherapy regimens-VA (Venetoclax + Azacitidine) and D/IA (Daunorubicin/Idarubicin + Cytarabine)-in elderly patients (aged 55-75) with acute myeloid leukemia (AML) who are fit for intensive chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Excluded: PML fusion with RARA
Acute promyelocytic leukemia with PML-RARA fusion gene
Excluded: RUNX1 fusion with RUNX1T1
AML with RUNX1-RUNX1T1 fusion gene
Excluded: CBFB fusion with MYH11
AML with CBFB-MYH11 fusion gene
Excluded: BCR fusion with ABL
AML with BCR-ABL fusion gene
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: induction chemotherapy
Exception: hydroxyurea is allowed
Relapsed or refractory AML (previously treated with induction chemotherapy, but hydroxyurea is allowed)
Lab requirements
Kidney function
Serum creatinine <2× ULN
Liver function
Total bilirubin ≤1.5× ULN; AST and ALT ≤2.5× ULN
Cardiac function
Cardiac enzymes <2× ULN; LVEF within normal range (by echocardiogram)
Adequate organ function: Total bilirubin ≤1.5× ULN; AST and ALT ≤2.5× ULN; Serum creatinine <2× ULN; Cardiac enzymes <2× ULN; LVEF within normal range
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify